An Open, Multi-center, Ib/II Clinical Trial of KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma
Latest Information Update: 02 Nov 2022
At a glance
- Drugs Erfonrilimab (Primary) ; Ningetinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Alphamab Biopharmaceuticals
- 26 Oct 2022 Status changed from active, no longer recruiting to discontinued.
- 16 May 2022 Status changed from not yet recruiting to active, no longer recruiting.
- 28 Oct 2020 New trial record